Active Pharmaceutical Ingredients (API), popularly speaking, are the raw materials of medicines, only pharmaceutical raw materials are processed into pharmaceutical preparations , can they become medicines available for clinical use, so drugs we usually eat are the finished drugs through processing. Active Pharmaceutical Ingredients based on its sources can be divided into two major categories ,including chemical synthetic drugs and natural chemical drugs. Chemical synthetic drugs can be divided into organic synthetic drugs and inorganic synthetic drugs. Inorganic synthetic drugs are inorganic compounds ( very few is element), such as aluminum hydroxide, magnesium trisilicate which are used for the treatment of gastric and duodenal ulcers ; organic synthetic drugs are mainly composed of drugs made by basic organic chemical raw materials, through a series of organic chemical reactions (such as aspirin, chloramphenicol, caffeine, etc.). Natural chemical drugs ,based on its sources,can be divided into two categories including biochemical drugs and plant chemical drugs. Antibiotics are generally made by the microbial fermentation, which belongs to the biochemistry category. A variety of semi-synthetic antibiotics occurs in recent years,which are biosynthesis and chemical synthesis combining products.Among active Pharmaceutical Ingredients, the organic synthetic drugs varieties, yields and values have the largest proportion,which are the main pillars of the chemical and pharmaceutical industries. The quality of active Pharmaceutical Ingredients decides whether the formulation is good or bad , so its quality standards are very strict ,countries in the world have developed national pharmacopoeia standards and strict quality control methods for its widely used active Pharmaceutical ingredients.
Understanding the Side Effects and Dosage of MK 677
MK 677 may cause water retention and hunger. Optimal dosage is 25mg/day to avoid side effects. Consult a healthcare professional before use for safety.
Feb 19,2024 APIDaptomycin: Unique Mechanism, Immunomodulating Potential, and Intracellular Bactericidal Activity
Daptomycin, a unique lipopeptide antibiotic, effectively disrupts Gram-positive bacterial membranes and modulates immune responses, promising for osteomyelitis treatment.
Feb 19,2024 APIVardenafil Hydrochloride: Pharmacodynamics and Methods of Preparation
Vardenafil hydrochloride effectively treats erectile dysfunction by enhancing cGMP levels, offering higher potency and tolerability with a well-established synthesis process.
Feb 19,2024 APIEsomeprazole Magnesium: Overview, Side Effects and Dosage
Esomeprazole magnesium treats acid-related disorders with specific dosages, requiring caution due to potential severe side effects.
Feb 19,2024 APIFondaparinux sodium: Pharmacokinetic Profile and Drug Interaction
Fondaparinux sodium exhibits favorable pharmacokinetics, minimal drug interactions, and reliable antithrombotic efficacy, making it a versatile clinical anticoagulant.
Feb 19,2024 APIFavipiravir: A Repurposed Antiviral Drug Showing Promising COVID-19 Treatment
Favipiravir shows promise in treating COVID-19 by inhibiting virus replication, with effectiveness dependent on a higher dosing regimen than for influenza.
Feb 19,2024 APILuliconazole: An Antifungal Agent with High Safety Profile in Onychomycosis Treatment
Luliconazole is an effective, safe antifungal with rapid action against onychomycosis, showing superior efficacy and tolerability in treatment.
Feb 19,2024 APIMethenolone acetate: Biological Functions, Applications in the Fitness Industry and Dosage
Methenolone acetate enhances muscle growth and performance, synergizes in bulking, preserves during cutting, and maintains gains with specific dosage recommendations.
Feb 19,2024 APISuvorexant: Mechanism of Action and Clinical Studies
Suvorexant effectively treats insomnia by inhibiting orexin neurotransmitters, demonstrated through extensive Phase I-III trials, offering a novel alternative to traditional hypnotics.
Feb 19,2024 APILorlatinib (PF-06463922): Overview and Therapeutic Trials in Non-Small Cell Lung Cancer
Lorlatinib (PF-06463922), a third-generation TKI by Pfizer, effectively treats ALK/ROS1-positive NSCLC, overcoming resistance and penetrating the blood-brain barrier with notable efficacy.
Feb 19,2024 API